Platelet-Rich Plasma (PRP) — Lexicon of the Business of Modern Medicine™

Regenerative Medicine

Platelet-Rich Plasma (PRP)

12 min readLast reviewed: June 2025AJ Pakpour, Healthcare Practice Startup & Strategy Expert
PRPplatelet-rich plasmaregenerative medicineautologousorthopedics

Definition

Platelet-Rich Plasma (PRP) is an autologous blood-derived preparation in which the concentration of platelets — and the growth factors they contain — is significantly higher than in whole blood, prepared by centrifugation of the patient's own blood and used in orthopedics, aesthetics, hair restoration, and wound care as a regenerative treatment.

Comprehensive Definition

Platelet-Rich Plasma (PRP) is prepared by drawing a sample of the patient's own (autologous) blood, processing it through one or two rounds of centrifugation to concentrate the platelet fraction, and then using the resulting preparation for therapeutic injection or topical application. The platelet concentration in PRP is typically 3 to 5 times higher than in whole blood, though this varies depending on the preparation system used and the patient's baseline platelet count. The therapeutic rationale for PRP is based on the growth factors and other bioactive molecules released by platelets upon activation, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF-1).

PRP preparations vary significantly in their composition depending on the centrifugation protocol, the collection system, and whether leukocytes are included or excluded. Leukocyte-rich PRP (LR-PRP) contains a significant concentration of white blood cells in addition to platelets, while leukocyte-poor PRP (LP-PRP) is depleted of leukocytes. The clinical significance of this distinction is debated, with some evidence suggesting that LR-PRP may be more effective for certain applications (such as tendon injuries) while LP-PRP may be preferable for others (such as intra-articular injections for osteoarthritis). The lack of standardization in PRP preparation is one of the major challenges in interpreting the clinical literature.

Clinical applications of PRP span multiple specialties. In orthopedics, PRP is used for the treatment of tendinopathies (particularly lateral epicondylitis and patellar tendinopathy), osteoarthritis (particularly of the knee), and ligament and muscle injuries. In aesthetics, PRP is used for facial rejuvenation (the "vampire facial"), under-eye treatment, and skin texture improvement. In hair restoration, PRP is injected into the scalp to stimulate hair follicle activity in patients with androgenetic alopecia. In wound care, PRP is applied topically or injected to promote healing of chronic wounds and surgical sites.

From a regulatory standpoint, PRP prepared from the patient's own blood is generally considered an autologous blood product and is exempt from FDA drug approval requirements under 21 CFR Part 1271. Because PRP is derived from the patient's own blood, processed minimally (centrifugation), and used for the same patient, it does not trigger the HCT/P regulatory framework in the same way that allogeneic products do. The FDA has generally not regulated autologous PRP as a drug or biologic, though the agency has noted that PRP preparation systems (the centrifuge devices and collection kits) are regulated as medical devices.

The clinical evidence base for PRP is substantial but heterogeneous. There are numerous randomized controlled trials and systematic reviews evaluating PRP for various indications, with the strongest evidence for knee osteoarthritis and lateral epicondylitis. However, the heterogeneity of PRP preparations across studies makes it difficult to draw definitive conclusions about efficacy, and the evidence for many applications remains limited.

Why It Matters

PRP represents one of the most accessible and legally straightforward regenerative medicine services that healthcare operators can offer. Because it is autologous — derived from the patient's own blood — it avoids the complex regulatory issues associated with allogeneic products like Wharton's Jelly or exosomes. The preparation equipment is widely available, the procedure is relatively simple, and the cost of goods is low compared to allogeneic regenerative medicine products.

For operators building cash-pay revenue streams, PRP is an attractive option. Most payers do not cover PRP for most indications, which means that PRP services are typically offered on a cash-pay basis. The combination of low cost of goods, high patient demand, and cash-pay pricing makes PRP a potentially high-margin service for practices that can build a patient base for it.

Understanding the evidence base and appropriate patient selection for PRP is essential for operators who want to offer it responsibly. PRP is not a panacea, and the evidence for its efficacy varies significantly across indications. Operators who make exaggerated claims about PRP's effectiveness or who use it for indications where the evidence is weak expose themselves to patient dissatisfaction, malpractice risk, and regulatory scrutiny.

Historical Background

The use of platelet concentrates in medicine dates to the 1970s, when fibrin glue — a preparation containing concentrated platelets and fibrinogen — was used in surgical settings to promote hemostasis and wound healing. The term "platelet-rich plasma" and the concept of using PRP for regenerative purposes emerged in the 1990s, initially in oral and maxillofacial surgery.

The use of PRP in orthopedics gained significant public attention in the late 2000s and early 2010s, when several high-profile professional athletes — including Tiger Woods and Kobe Bryant — reported using PRP injections for sports injuries. This publicity generated widespread patient interest in PRP and drove rapid growth in the market for PRP preparation systems and clinical services.

The scientific literature on PRP has grown substantially over the past two decades, with hundreds of clinical trials evaluating PRP for various indications. The quality of this literature has improved over time, with more recent studies using better-defined PRP preparations and more rigorous study designs. However, the heterogeneity of PRP preparations and the lack of standardization in the field continue to complicate the interpretation of the evidence.

Federal Regulations

Autologous PRP prepared from the patient's own blood is generally exempt from FDA drug approval requirements. The FDA has not regulated autologous PRP as a drug or biologic, taking the position that it is an autologous blood product that does not trigger the HCT/P regulatory framework under 21 CFR Part 1271.

PRP preparation systems — the centrifuge devices and collection kits used to prepare PRP — are regulated as medical devices under the Federal Food, Drug, and Cosmetic Act. Several PRP preparation systems have received FDA 510(k) clearance as Class II medical devices. Operators should use FDA-cleared PRP preparation systems to ensure that their preparation process meets applicable quality standards.

The FDA has not approved PRP as a treatment for any specific indication. While autologous PRP is generally not subject to FDA drug approval requirements, operators should be cautious about making claims that PRP is FDA-approved or that it has been proven effective for specific conditions, as these claims may be misleading.

State Considerations

The administration of PRP is generally within the scope of practice of licensed physicians, physician assistants, nurse practitioners, and other licensed healthcare providers, subject to state scope of practice laws. Operators should verify that the practitioners who administer PRP in their facility are licensed to perform the procedure under applicable state law.

Some states have enacted specific regulations or issued guidance on the use of regenerative medicine products, including PRP. Operators should be aware of any state-specific requirements in the states where they practice.

The marketing of PRP services is subject to state consumer protection laws and FTC regulations governing advertising claims. Operators who make unsubstantiated claims about PRP's effectiveness may be subject to enforcement action by state attorneys general or the FTC.

Common Mistakes

  • Using PRP preparation systems that are not FDA-cleared as medical devices — operators should verify that their preparation system has received FDA 510(k) clearance.
  • Making claims that PRP is FDA-approved for specific indications — PRP is not FDA-approved as a treatment for any indication, and making such claims is misleading.
  • Not standardizing the PRP preparation protocol within the practice — variability in centrifugation speed, time, and collection volume can significantly affect the composition and quality of the PRP preparation.
  • Offering PRP for indications where the evidence base is weak without appropriate patient counseling about the limitations of the evidence.
  • Not maintaining appropriate documentation of PRP procedures, including the preparation protocol, platelet concentration (if measured), and patient outcomes.
  • Failing to screen patients for contraindications to PRP, including active infection, bleeding disorders, anticoagulant therapy, and certain malignancies.

Operator Insight

PRP is one of the most straightforward regenerative medicine services to implement from a regulatory standpoint, and it can be a meaningful revenue driver for the right practice. The key to building a successful PRP service is patient selection and expectation management. PRP works best for patients with appropriate indications — knee osteoarthritis, lateral epicondylitis, androgenetic alopecia — and the evidence for these indications is reasonably strong. For indications where the evidence is weaker, I advise operators to be transparent with patients about the limitations of the data. The economics of PRP are attractive. The cost of goods — the PRP preparation kit and the practitioner's time — is relatively low, and cash-pay pricing for PRP injections typically ranges from $500 to $1,500 per treatment, depending on the indication and the market. For practices that can build a referral base for PRP, the service can generate meaningful revenue with a favorable margin profile. One thing I emphasize to operators is the importance of using a standardized, validated PRP preparation protocol. The clinical literature on PRP is full of studies that are difficult to interpret because the PRP preparation was not well characterized. If you want to be able to track outcomes and improve your clinical results over time, you need to know what you are injecting. Invest in a quality PRP preparation system, measure platelet concentration, and document your protocol consistently.

— AJ Pakpour, Healthcare Practice Startup & Strategy Expert

In Practice

An orthopedic practice adds PRP injections to its service menu for patients with knee osteoarthritis and lateral epicondylitis. The practice selects an FDA-cleared PRP preparation system, develops a standardized preparation protocol, and trains its clinical staff on the procedure. The practice implements an outcomes tracking system to monitor patient results and uses this data to refine its patient selection criteria and preparation protocol over time. PRP injections are offered on a cash-pay basis at $800 per treatment, with a recommended series of three injections for knee osteoarthritis. A dermatology practice offers PRP for hair restoration in patients with androgenetic alopecia. The practice uses a standardized PRP preparation protocol and offers a series of four treatments spaced one month apart, followed by maintenance treatments every six months. The practice tracks patient outcomes using standardized hair density measurements and patient satisfaction surveys, and uses this data to counsel prospective patients about realistic expectations for treatment outcomes.

Frequently Asked Questions

References

  1. 1.FDA: Regulatory Considerations for Autologous Blood Products
  2. 2.Cochrane Review: PRP for Knee Osteoarthritis
  3. 3.AAOS: Clinical Practice Guideline — Management of Osteoarthritis of the Knee
  4. 4.AMA CPT: Category III Codes — 0232T

Further Reading

Turn Knowledge Into Action

Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.

Book a Strategy Session